leflunomide (lef), used for rheumatoid arthritis, inhibits dihydro-orotate dehydrogenase (dhodh) and tyrosine kinase (tk) enzymes and has anti-inflammatory, lymphocyte proliferation regulatory, immunosuppression and chondroprotective effects. the most common adverse effects are gastrointestinal disorders, weight loss, hypertension, skin infection, and neurological and hematological toxicity. it...

jak2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. a single acquired point mutation – v617f – in jak2 occurs in the great majority of patients with polycythemia vera (pv) and approximately half of the patients with idiopathic myelofibrosis (imf) or essential thrombocythemia (et). in contrast, the jak2-v617f mutation is...

Summary Chronic myeloid leukemia is nowadays associated with a good prognosis and an excellent life expectancy. However, certain levels of responses have to be achieved the various available tyrosine kinase inhibitors at time points during treatment otherwise adequate diagnostic therapeutic actions initiated. This paper will focus on these issues.

Leflunomide (LEF), used for rheumatoid arthritis, inhibits dihydro-orotate dehydrogenase (DHODH) and tyrosine kinase (TK) enzymes and has anti-inflammatory, lymphocyte proliferation regulatory, immunosuppression and chondroprotective effects. The most common adverse effects are gastrointestinal disorders, weight loss, hypertension, skin infection, and neurological and hematological toxicity. It...

Introduction The receptor tyrosine kinase Axl is described as a driver for migration and metastasis well resistance against molecular targeting agents radio- chemotherapy (RCT) in various tumor entities including head neck squamous cell carcinoma (HNSCC). For the latter, clinical data describing impact of its ligand Gas6 on patient outcome are sparse.